This is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on the company's proprietary ProCellExtm protein. This stock closed up 8.8% to $5.31 in recent trading.
Today's Range: $4.97-$5.56
52-Week Range: $4.71-$7.70Volume: 744,000 Three-Month Average Volume: 145,775 Shares of PLX exploded higher after the Globes reported the company is close to signing an agreement for selling its Gaucher's disease treatment to the government of Brazil. The deal is reportedly worth hundreds of millions of dollars. From a technical perspective, PLX ripped higher today back above its 50-day moving average of $5.05 with monster upside volume. This move also pushed PLX into breakout territory, since the stock took out some near-term overhead resistance levels at $5.19 to $5.40. Shares of PLX are now trending within range of triggering another major breakout trade. That trade will hit once PLX manages to take out some more overhead resistance levels at $5.80 to $6.07 with high volume. Traders should now look for long-biased trades in PLX as long as it's trending above $5.40, and then once it sustains a move or close above those breakout levels with volume that hits near or above 154,775 shares. If that breakout triggers soon, then look for PLX to re-test or possibly take out its next major overhead resistance levels at $6.80 to $7. Any high-volume move above $7 would then put $7.70 into focus for PLX. Insmed (INSM) This is a development-stage biopharmaceutical company. The company develops inhaled treatments for serious lung infections. This stock closed up 7.5% to $7.51 in recent trading. Today's Range: $6.90-$7.70 52-Week Range: $2.64-$7.17 Volume: 822,000 Three-Month Average Volume: 147,395 Shares of INSM trended up today after the company said its CLEAR-108 phase 3 clinical study of Arikace in Cystic Fibrosis patients with pseudomonas lung infections has completed target enrollment. From a technical perspective, INSM trended up strongly today with monster upside volume. This move has now pushed INSM into breakout territory, since the stock cleared some near-term overhead resistance levels at $7.14 to $7.17.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts